Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9

Blood

Volumn 119, Issue 13, 2012, Pages 3064-3072

  Gleason, Michelle K ^a   Lenvik, Todd R ^a   McCullar, Valarie ^a   Felices, Martin ^a   O'Brien, M Shea ^a   Cooley, Sarah A ^a   Verneris, Michael R ^a   Cichocki, Frank ^a   Holman, Carol J ^b   Panoskaltsis Mortari, Angela ^a   Niki, Toshiro ^c   Hirashima, Mitsuomi ^c   Blazar, Bruce R ^a   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ECALECTIN; GAMMA INTERFERON; I KAPPA B ALPHA; INTERLEUKIN 12; INTERLEUKIN 18; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; NATURAL KILLER CELL RECEPTOR; TIM 3 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CELL ENGINEERING; CELL TRANSPLANTATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; ENZYME ACTIVATION; HEMATOPOIETIC CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAJI CELL; SIGNAL TRANSDUCTION;

EID: 84859192882     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-360321     Document Type: Article

References (50)

1. Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev. 2006;214:56-72. (Pubitemid 44707902)
2. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and new insights into the graft versus leukemia effect. Blood. 2002;100(6):1935-1947. (Pubitemid 35001221)
3. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002;2(10):735-747. (Pubitemid 37328714)
4. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med. 1998;188(12):2375- 2380. (Pubitemid 29028510)
5. Perussia B. Fc receptors on natural killer cells. Curr. Top. Microbiol Immunol. 1998;230:63-88.
6. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187-376. (Pubitemid 20010960)
7. Miller JS. The biology of natural killer cells in cancer, infection and pregnancy. Exp Hematol. 2001;29(10):1157-1168. (Pubitemid 32936575)
8. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051-3057.
9. Lanier LL. NK cell recognition. Ann Rev Immunol. 2005;23:225-274. (Pubitemid 40563170)
10. Chung JW, Yoon SR, Choi I. The regulation of NK cell function and development. Front Biosci. 2008;13:6432-6442.
11. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 2010;115(11):2167-2176.
12. Anderson AC, Lord GM, Dardalhon V, et al. T-bet, a Th1 transcription factor regulates the expression of Tim-3. Eur J Immunol. 2010;40(3):859-866.
13. Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415(6871):536-541. (Pubitemid 34130609)
14. Wang F, He W, Zhou H, et al. The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cells and prolongs survival of skin graft. Cell Immunol. 2007;250(1-2):68-74.
15. Anderson AC, Anderson DE, Bregoli L, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318(5853):1141-1143. (Pubitemid 350134897)
16. Khademi M, Illés Z, Gielen AW, et al. T cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol. 2004;172(11):7169-7176. (Pubitemid 38669161)
17. Zhao J, Lei Z, Liu Y, et al. Human pregnancy up-regulates Tim-3 in innate immune cells for systemic immunity. J Immunol. 2009;182(10):6618-6624.
18. Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type I immunity. Nat Immunol. 2005;6(12):1245- 1252. (Pubitemid 43045636)
19. Wada J, Kanwar YS. Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem. 1997;272(9):6078-86. (Pubitemid 27102450)
20. Sabatos CA, Chakravarti S, Cha E, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and peripheral tolerance. Nat Immunol. 2003;4(11):1102-1110. (Pubitemid 37428038)
21. Jones RB, Ndhlovu LC, Barbour JD, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 2008;205(12):2763-2779.
22. Rabinovich GA, Rubinstein N, Toscano MA. Role of galectins in inflammatory and immunomodulatory processes. Biochim Biophys Acta. 2002;1572(2-3):274-284. (Pubitemid 35246350)
23. Seki M, Oomizu S, Sakata KM, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol. 2008;127(1):78-88.
24. Zhou Q, Munger ME, Veenstra RG, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117(17):4501-4510.
25. Nobumoto A, Oomizu S, Arikawa T, et al. Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice. Clin Immunol. 2009;130(3):322-330.
26. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94(1):333-339. (Pubitemid 29300166)
27. Guimaraes F, Guven H, Donati D, et al. Evaluation of ex vivo expanded human NK cells on anti-leukemia activity in SCID-beige mice. Leukemia. 2006;20(5):833-839.
28. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113(3):726-732.
29. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411-2419.
30. Huntington ND, Xu Y, Nutt SL, Tarlington DM. A requirement for CD45 distinguishes Ly49D-mediated cytokine and chemokine production from killing in primary natural killer cells. J Exp Med. 2005;201(9):1421-1433. (Pubitemid 40664086)
31. Cao E, Zang X, Ramagopal UA, et al. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity. 2007;26(3):311-321. (Pubitemid 46413908)
32. DeKruyff RH, Bu X, Ballesteros A, et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol. 2010;184(4):1918-1930.
33. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442(7101):461-465. (Pubitemid 44264796)
34. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133-146. (Pubitemid 37328691)
35. Nguyen S, Dhedin N, Vernant JP, et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood. 2005;105(10):4135- 4142. (Pubitemid 40656166)
36. Ju Y, Hou N, Meng J, et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer suppression in chronic hepatitis B. J Hepatol. 2010;52(3):322-329.
37. Nagahara K, Arikawa T, Oomizu S, et al. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances anti-tumor immunity via galection-9-Tim-3 interactions. J. Immunol. 2008;181(11):7660-7669.
38. Ju Y, Hou N, Zhang XN, et al. Blockade of Tim-3 pathway ameliorates interferon-gamma production from hepatic CD8+ T cells in a mouse model of hepatitis B virus infection. Cell Mol Immunol. 2009;6(1):35-43.
39. Lee J, Su EW, Zhu C, et al. Phosphotyrosine-dependent coupling of tim-3 to T-cell receptor signaling pathways. Mol Cell Biol. 2011;31(19):3963-3974.
40. Bloch-Queyrat C, Fondanèche MC, Chen R, et al. Regulation of natural cytotoxicity by the adaptor SAP and the Src-related kinase Fyn. J Exp Med. 2005;202(1):181-192. (Pubitemid 41002920)
41. Roncagalli R, Taylor JE, Zhang S, et al. Negative regulation of natural killer cell function by EAT-2, a SAP-related adaptor. Nat Immunol. 2005;6(10):1002-1010. (Pubitemid 41486185)
42. Eissmann P, Beauchamp L, Wooters J, Tilton JC, Long EO, Watzl C. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood. 2005;105(12):4722-4729. (Pubitemid 40807295)
43. Xiao S, Najafian N, Reddy J, et al. Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J Exp Med. 2007;204(7):1691-702. (Pubitemid 47048034)
44. Rajagopalan S, Fu J, Long EO. Cutting edge: induction of IFN-gamma production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells. J Immunol. 2001;67(4):1877-1881. (Pubitemid 32747490)
45. Chuang SS, Kumaresan PR, Mathew PA. 2B4 (CD244)-mediated activation of cytotoxicity and IFN-gamma release in human NK cells involves distinct pathways. J Immunol. 2001;167(11):6210-6216. (Pubitemid 33081549)
46. Yu WG, Ogawa M, Mu J, et al. IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways. J Leukoc Biol. 1997;62(4):450-457. (Pubitemid 27459773)
47. Mandal M, Bandyopadhyay D, Goepfert TM, Kumar R. Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene. 1998;16(2):217-225. (Pubitemid 28045108)
48. Xu X, Fu XY, Plate J, Chong AS. IFN-gamma induces cell growth inhbition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 1998;58(13):2832-2837. (Pubitemid 28311915)
49. Appelbaum FR. Hematopoietic cell transplantation for adult acute myeloid leukemia. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, eds. Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, 4th ed. Malden, MA: Blackwell Publishing; 2009:761-774.
50. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-100. (Pubitemid 34229476)